Bristol-Myers Squibb. has filed a patent for compounds that inhibit KRas G12D activity. The invention includes specific compounds, pharmaceutical compositions, and methods of use. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bristol-Myers Squibb Co - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

A patent application (Publication Number: US20240034733A1) has been filed for a compound represented by Formula (I) and its various derivatives. The compound or salt of the formula includes specific substitutions on the hexahydro-1H-pyrrolizinyl group, such as halogen or alkyl groups. Additionally, the patent covers methods for inhibiting KRas G12D activity in cells and treating various cancers by administering the compound or its salt.

The compound described in the patent application shows potential for inhibiting KRas G12D activity in cells and treating cancers associated with KRas G12D mutations. The patent application also includes specific dosages for administering the compound to patients in need of cancer treatment, ranging from 0.01 to 100 mg/kg per day. Furthermore, the patent application outlines the types of cancers that can be treated using the compound, including non-small cell lung cancer, small cell lung cancer, colorectal cancer, rectal cancer, and pancreatic cancer. Overall, the patent application provides a detailed description of the compound's structure, potential therapeutic applications, and methods for treating cancer associated with specific mutations.

To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies